1,3-Dimethyl-pyrido<3.4-d>pyrimidin-2,4-(1H,3H)-dion | 22389-83-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶并嘧啶类
• 英文名称: 1,3-Dimethyl-pyrido<3.4-d>pyrimidin-2,4-(1H,3H)-dion
• 英文别名: 1,3-Dimethylpyrido[3,4-d]pyrimidine-2,4(1H,3H)-dione；1,3-dimethylpyrido[3,4-d]pyrimidine-2,4-dione
• CAS: 22389-83-9
• 化学式: C₉H₉N₃O₂
• 分子量: 191.189
• InChiKey: SZBJSOAGZFIRNV-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.3
• 重原子数：
  14
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.22
• 拓扑面积：
  53.5
• 氢给体数：
  0
• 氢受体数：
  3

文献信息

• HYDROXYL PURINE COMPOUNDS AND USE THEREOF
  申请人：GUANGDONG ZHONGSHENG PHARMACEUTICAL CO., LTD

  公开号：US20180148451A1

  公开（公告）日：2018-05-31

  Disclosed are a series of hydroxyl purine compounds and the use thereof as PDE2 or TNFα inhibitors, in particular, the compounds as shown in formula (I), or tautomers or pharmaceutically acceptable salts thereof.

  揭示了一系列的羟基嘌呤化合物及其作为PDE2或TNFα抑制剂的用途，特别是如公式(I)所示的化合物，或其互变异构体或药用可接受的盐。
• [EN] COMPOUNDS FOR INHIBITION OF ALPHA 4 BETA 7 INTEGRIN<br/>[FR] COMPOSÉS POUR L'INHIBITION DE L'INTÉGRINE ALPHA 4 BÊTA 7
  申请人：GILEAD SCIENCES INC

  公开号：WO2021030438A1

  公开（公告）日：2021-02-18

  The present disclosure provides a compound of Formula (I): or a pharmaceutically acceptable salt thereof as described herein. The present disclosure also provides pharmaceutical compositions comprising a compound of Formula (I), processes for preparing compounds of Formula (I), therapeutic methods for treating inflammatory disease.

  本公开提供了化合物的化学式(I)：或其药用可接受的盐，如本文所述。本公开还提供了包含化合物的药物组合物的配方(I)，制备化合物的方法(I)，治疗炎症性疾病的治疗方法。
• NOVEL PHENYLALANINE DERIVATIVES
  申请人：SAGI Kazuyuki

  公开号：US20080108634A1

  公开（公告）日：2008-05-08

  Specific phenylalanine derivatives and analogues thereof have an antagonistic activity to α4 integrin. They are used as therapeutic agents for various diseases concerning α4 integrin.

  特定的苯丙氨酸衍生物及其类似物具有对α4整合素的拮抗活性。它们被用作治疗与α4整合素相关的各种疾病的治疗剂。
• Hydroxyl purine compounds and use thereof
  申请人：GUANGDONG RAYNOVENT BIOTECH CO., LTD.

  公开号：US10278973B2

  公开（公告）日：2019-05-07

  Disclosed are a series of hydroxyl purine compounds and the use thereof as PDE2 or TNFα inhibitors, in particular, the compounds as shown in formula (I), or tautomers thereof or pharmaceutically acceptable salts thereof.

  公开了一系列羟基嘌呤化合物及其作为 PDE2 或 TNFα 抑制剂的用途，特别是如式 (I) 所示的化合物或其同系物或其药学上可接受的盐。
• Quinoline derivatives
  申请人：Gilead Sciences, Inc.

  公开号：US11116760B2

  公开（公告）日：2021-09-14

  The present disclosure provides a compound of Formula (I): or a pharmaceutically acceptable salt thereof as described herein. The present disclosure also provides pharmaceutical compositions comprising a compound of Formula (I), processes for preparing compounds of Formula (I), and therapeutic methods for treating inflammatory disease.

  本公开提供了一种式 (I) 的化合物： 或其药学上可接受的盐。本公开还提供了包含式（I）化合物的药物组合物、制备式（I）化合物的工艺以及治疗炎症性疾病的治疗方法。